Correlation analysis of serum PTX3 expression and bone metastasis in non-small cell lung cancer

doi:10.3877/cma.j.issn.1674-6902.2024.04.010

Abstract

Abstract:

Objective

To analyze the correlation and clinical significance of serum pentraxin 3 (PTX3) expression with bone metastasis of non-small cell lung cancer (NSCLC).

Methods

A total of 184 metastatic NSCLC patients treated in Tangdu Hospital from September 2022 to July 2023 were selected. 69 cases of NSCLC bone metastasis were the observation group, and 115 cases of NSCLC non-bone metastasis were the control group. The clinical information of patients was collected, and the expression level of serum PTX3 was detected by enzyme-linked immunosorbent assay (ELISA). Compared serum PTX3 content of two groups, we analyze the correlation of PTX3 expression with NSCLC bone metastases and compared serum PTX3 expression in NSCLC bone metastases before and after treatment. Receiver operating characteristic (ROC) curve was used to determine the diagnostic value of serum PTX3 for NSCLC bone metastasis.

Results

There were no significant differences in gender and age between the two groups (P>0.05). There were 69 cases of bone metastasis in the observation group and 40 cases of lymph node metastasis, 31 cases of lung metastasis, 21 cases of brain metastasis, 14 cases of liver metastasis and 12 cases of adrenal metastasis in the control group. The serum PTX3 in the observation group was 104.80 (175.48) ng/ml, which was higher than that in the control group 21.48 (22.02) ng/ml (P<0.05). There were no significant differences of serum PTX3 expression in NSCLC bone metastasis patients with different clinical characteristics, including gender, age, history of cancer, smoking index, BMI index, pathological type, primary tumor location, single organ metastasis, number of metastatic lesions, nature of bone metastasis, blood calcium and serum alkaline phosphatase (P>0.05). There was no significant difference in the expression of serum PTX3 in NSCLC patients with bone metastasis before and after clinical treatment(P>0.05). The area under ROC curve of serum PTX3 in the diagnosis of NSCLC with bone metastasis was 0.860(95%CI: 0.802~0.919), with the optimal diagnostic cut-off value, sensitivity and specificity of 35.385 ng/ml, 0.855 and 0.748, respectively.

Conclusions

The high expression of serum PTX3 is closely related to the bone metastasis of NSCLC, which has a good diagnostic value for NSCLC bone metastasis and clinical significance.s

Key words: Non-small cell lung cancer, Pentraxin 3, Bone metastasis, Correlation analysis

Duo Li, Zhaozhao Hao, Yanwei Chen, Yandong Nan. Correlation analysis of serum PTX3 expression and bone metastasis in non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 558-562.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2024.04.010

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2024/V17/I04/558

Figures/Tables 3

References 30

1	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024，74(3): 229-263.
2	吴国明，钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
3	Shi S, Wang H, Liu X, et al. Prediction of overall survival of non-small cell lung cancer with bone metastasis: an analysis of the Surveillance, Epidemiology and End Results (SEER) database[J]. Transl Cancer Res, 2021, 10(12): 5191-5203.
4	Cho YJ, Cho YM, Kim SH, et al. Clinical analysis of patients with skeletal metastasis of lung cancer[J]. BMC Cancer, 2019, 19(1): 303.
5	Li Y, Zhang S, Liu J, et al. The pentraxin family in autoimmune disease[J]. Clin Chim Acta, 2023, 551: 117592.
6	Giacomini A, Ghedini GC, Presta M, et al. Long pentraxin 3: A novel multifaceted player in cancer[J]. Biochim Biophys Acta Rev Cancer, 2018, 1869(1): 53-63.
7	Li D, Hao Z, Nan Y, et al. Role of long pentraxin PTX3 in cancer[J]. Clin Exp Med, 2023, 23(8): 4401-4411.
8	Bottazzi B, Inforzato A, Messa m, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling[J]. J Hepatol, 2016, 64(6): 1416-1427.
9	Choi B, Lee EJ, Song DH, et al. Elevated pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function[J]. Oncotarget, 2014, 5(2): 481-492.
10	Choi B, Lee EJ, Shin MK, et al. Upregulation of brain-derived neurotrophic factor in advanced gastric cancer contributes to bone metastatic osteolysis by inducing long pentraxin 3[J]. Oncotarget, 2016, 7(34): 55506-55517.
11	Granata V, Strina D, Schiavone ML, et al. Genetic deficiency of the long pentraxin 3 affects osteogenesis and osteoclastogenesis in homeostatic and inflammatory conditions[J]. Int J Mol Sci, 2023, 24(23): 16648.
12	Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2020, 31(12): 1650-1663.
13	崔永元，宋　敏，刘乾坤，等. 甲状旁腺素对骨代谢相关疾病的影响研究进展[J]. 系统医学，2023, 8(15): 195-198.
14	周于琳，冯正平. 糖皮质激素诱导骨质疏松发病机制的研究进展[J]. 中国骨质疏松杂志，2023, 29(2): 288-291.
15	黄毅勇. 慢性肾病矿物质和骨代谢异常的血清学诊断的临床研究[J/CD]. 临床检验杂志(电子版), 2020, 9(1): 70.
16	Thomson M, Scott A, Trost S, et al. Low screening rates and high prevalence of osteoporosis in cirrhosis: A real-world retrospective analysis[J]. Aliment Pharmacol Ther, 2024, 59(4): 535-546.
17	Jansen RB, Nilsson J, Buch-Larsen K, et al. Treatment effect of zoledronic acid in chronic non-bacterial osteomyelitis of the jaw: A case series[J]. Calcif Tissue Int, 2024, 114(2): 129-136.
18	Da SILVA G T, Bergmann A, Thuler LCS. Incidence and risk factors for bone metastasis in non-small cell lung cancer[J]. Asian Pac J Cancer Prev, 2019, 20(1): 45-51.
19	Sterling JA, Edwards JR, Martin TJ, et al. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior[J]. Bone, 2011, 48(1): 6-15.
20	Wu S, Pan Y, Mao Y, et al. Current progress and mechanisms of bone metastasis in lung cancer: a narrative review[J]. Transl Lung Cancer Res, 2021, 10(1): 439-451.
21	De Leon-Oliva D, Barrena-Blázquez S, Jiménez-Álvarez L, et al. The RANK-RANKL-OPG system: A multifaceted regulator of homeostasis, immunity, and cancer[J]. Medicina (Kaunas), 2023, 59(10): 1752.
22	Chu T, Teng J, Jiang L, et al. Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation[J]. Biochem Biophys Res Commun, 2014, 443(3): 962-968.
23	Jiang T, Zeng Q, He J. Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors？[J]. Transl Cancer Res, 2023，12(10): 2932-2945.
24	Xie T, Chen S, Hao J, et al. Roles of calcium signaling in cancer metastasis to bone[J]. Explor Target Antitumor Ther, 2022，3(4): 445-462.
25	郭飞虎，成伟华，费月英，等. Na～(18)F PET/CT用于恶性肿瘤骨转移诊断的Meta分析[J]. 标记免疫分析与临床，2019, 26(5): 786-794.
26	陈　凤，崔亚利. 骨转移瘤影像学检查研究概述[J]. 医学综述，2019, 25(1): 134-138.
27	Chai X, Yinwang E, Wang Z, et al. Predictive and prognostic biomarkers for lung cancer bone metastasis and their therapeutic value[J]. Front Oncol, 2021, 11: 692788.
28	孟　超，汤传昊，梁　军. 肺癌骨转移诊断标记物研究进展[J]. 中国肺癌杂志，2018, 21(8): 615-619.
29	李秋实，杨　洁，庄　琰，等. 观察血清肿瘤标志物在肺癌骨转移诊断中的价值[J]. 航空航天医学杂志，2021, 32(12): 1432-1433.
30	Zang S, He Q, Bao Q, et al. Establishment and validation of a novel survival prediction scoring algorithm for patients with non-small-cell lung cancer spinal metastasis[J]. Int J Clin Oncol, 2019, 24(9): 1049-1060.

组　别	转移器官	例数	M(IQR)(ng/ml)	H值	P值
观察组	骨转移	69	104.80(175.48)	71.44	0.000
对照组	肺转移^ab	31	24.06(15.57)
	脑转移^b	21	20.61(29.92)
	肝转移^b	14	22.53(23.72)
	肾上腺转移^b	12	23.75(20.78)
	淋巴结转移^bc	40	21.91(41.84)

组　别	转移器官	例数	M(IQR)(ng/ml)	H值	P值
观察组	骨转移	69	104.80(175.48)	71.44	0.000
对照组	肺转移^ab	31	24.06(15.57)
	脑转移^b	21	20.61(29.92)
	肝转移^b	14	22.53(23.72)
	肾上腺转移^b	12	23.75(20.78)
	淋巴结转移^bc	40	21.91(41.84)

临床资料	变　量	例数	PTX3(ng/ml)	P值
性别				0.288
	男	38	86.27(176.91)
	女	31	116.63(176.07)
年龄(岁)				0.387
	≤60	34	102.55(151.93)
	>60	35	116.63(245.80)
癌症家族史				0.226
	无	59	89.52(162.47)
	有	10	166.07(290.60)
吸烟指数(支年)				0.475
	0	41	89.52(167.56)
	0～400	6	197.95(94.32)
	≥400	22	93.94(254.22)
BMI指数(kg/m²)				0.239
	<18.50	8	113.51(228.44)
	18.50～23.99	41	81.78(132.45)
	24.00～27.99	15	126.17(167.58)
	≥28.00	5	216.54(151.66)
病理类型				0.183
	腺癌	61	98.04(196.39)
	鳞癌	8	37.90(243.91)
原发灶位置				0.408
	中央	23	87.43(136.81)
	周围	43	104.86(195.81)
单器官转移				0.870
	否	51	100.30(176.56)
	是	18	115.52(206.10)
骨转移灶数量(个)				0.912
	≤2	21	104.80(133.67)
	3～5	26	91.26(158.54)
	>5	22	133.33(215.81)
骨转移性质				0.983
	溶骨性	47	104.86(183.48)
	成骨性	9	104.80(209.60)
	混合性	13	89.52(182.61)
高钙血症				0.264
	否	65	100.30(161.27)
	是	4	291.22(207.88)
高碱性磷酸酶血症				0.055
	否	41	87.43(119.90)
	是	28	189.10(243.64)

临床资料	变　量	例数	PTX3(ng/ml)	P值
性别				0.288
	男	38	86.27(176.91)
	女	31	116.63(176.07)
年龄(岁)				0.387
	≤60	34	102.55(151.93)
	>60	35	116.63(245.80)
癌症家族史				0.226
	无	59	89.52(162.47)
	有	10	166.07(290.60)
吸烟指数(支年)				0.475
	0	41	89.52(167.56)
	0～400	6	197.95(94.32)
	≥400	22	93.94(254.22)
BMI指数(kg/m²)				0.239
	<18.50	8	113.51(228.44)
	18.50～23.99	41	81.78(132.45)
	24.00～27.99	15	126.17(167.58)
	≥28.00	5	216.54(151.66)
病理类型				0.183
	腺癌	61	98.04(196.39)
	鳞癌	8	37.90(243.91)
原发灶位置				0.408
	中央	23	87.43(136.81)
	周围	43	104.86(195.81)
单器官转移				0.870
	否	51	100.30(176.56)
	是	18	115.52(206.10)
骨转移灶数量(个)				0.912
	≤2	21	104.80(133.67)
	3～5	26	91.26(158.54)
	>5	22	133.33(215.81)
骨转移性质				0.983
	溶骨性	47	104.86(183.48)
	成骨性	9	104.80(209.60)
	混合性	13	89.52(182.61)
高钙血症				0.264
	否	65	100.30(161.27)
	是	4	291.22(207.88)
高碱性磷酸酶血症				0.055
	否	41	87.43(119.90)
	是	28	189.10(243.64)

[1]	Xinzhao Li, Tingtao Zhang, Feng Zhu, Jinshan Liu, Dachuang Liu. The value of fibrinogen, D-dimer and alkaline phosphatase in the diagnosis of bone metastasis of prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 459-463.
[2]	Siping Hu, Xingyu Xiong, Hang Xu, Lu Yang. The mechanisms of senescence-associated secretory phenotype factors in the occurrence and progression of prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 425-434.
[3]	Mengmeng Zhao, Jie Huang, Ronghuan Yu, Baoqing Wang. Overexpression of the small GTPase Rab32 inhibits the invasive growth of non-small cell lung cancer cells [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 512-518.
[4]	Guiping Zhang, Yonglin Qiu, Qiting Zhan, Ledong Sun. Prognostic significance of serum Ape1/Ref-1 for the radioactive lung injury in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 519-523.
[5]	Xiaoyu Han, Keyu Li, Zhifei Zhao, Jianping Gao. Prognostic significance of SNHG17 overexpression for non-small cell lung cancer resection [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 543-547.
[6]	Song Liu, Jinzhao Zhang, Yanyun Jia. Relationship between reduced response to pabolizumab in treatment of advanced non-small cell lung cancer and antibiotic preconditioning [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 553-557.
[7]	Lili Bai, Yu Jiang, Liangliang Huang, Ying BAI, Min Zhang. Application of occupational therapy in postoperative rehabilitation of patients with non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 411-415.
[8]	Haiyan Zhao, Haitao Jin, ying Kong, Ruiyuan He. Prognostic significance of plasma NGS-ctDNA in patients with advanced NSCLC treated with EGFR-TKIs [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 385-391.
[9]	Jing Yang, Jian Fu, Yanxia Kang. Significance of plasma ctDNA T790M mutation and total metabolic tumor volume in the prognostic significance of TKIs treatment in patients with advanced EGFR mutant NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 379-384.
[10]	Zhen Wang, Lu Huang, Lianqun Lang, Lu Yue. Prognostic significance of platelet and albumin/fibrinogen ratio in second-line therapy of bevacizumab for advanced non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(01): 35-40.
[11]	Jing Li, Guoyuan Ling, Shan Jiang, Xiaoju Chen, Xiaoyun Guo. Efficacy of pemetrexed delivery via ommaya capsule implantation versus lumbar puncture in treatment of leptomeningeal metastasis of non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 128-132.
[12]	Meisi Liang, Huimin Lan, Ting Yu, Shengqiao Li. The study of plumbagin on suppressing the proliferation of non-small cell lung cancer [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(02): 120-125.
[13]	Zijian Li, Rui Wang, Yunpeng Zhong, Dixuan Zhang, Yunjuan Liang, Chao Yang, Jianxing He, Shuben Li. Clinical application of lung autotransplantation in thoracic malignancies [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(03): 193-200.
[14]	Xunfu Zhang, Jinshan Ma, Yunlong Jiang, Tuoleheng Jianati, Changjian Hou, Silajiding Sawuti. Expression and clinicopathological significance of GATA3 protein in non-small cell lung cancer tissues [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(03): 175-179.
[15]	Kuan Xu, Heng Zhao, Bo Ye. Interpretation of the surgical section of the 2024 first edition of the National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(02): 79-84.

Please choose a citation manager

Content to export